全球青光眼治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

全球青光眼治疗市场需求预计将从 2023 年的 76.6 亿美元增至 2032 年的近 121 亿美元，2024-2032 年研究期间CAGR为 5.21%。

青光眼的治疗涉及一系列医疗和手术干预措施，以管理和控制眼部疾病的进展。青光眼会导致视神经受损，这通常与眼压 (IOP) 升高有关。作为不可逆性失明的主要原因，青光眼目前无法治癒。然而，治疗策略的重点是防止视神经受到额外损伤并保留视力。

市场动态

全球青光眼盛行率不断上升，特别是在老年人口中，各种因素推动了青光眼治疗市场的发展。治疗方案的技术进步，包括雷射疗法和微创青光眼手术（MIGS），有助于扩大有效干预措施。意识的提高和早期检测工作强调了对多样化治疗方案的需求，以满足不同的患者需求。对 MIGS 等微创手术的偏好会影响患者的选择，从而缩短復原时间并改善预后。医疗保健支出的增加、政府支持眼健康的倡议以及行业利益相关者之间的合作推动了青光眼治疗的创新。竞争激烈的市场格局和持续的产品开发有助于引入新的和改进的治疗方式。此外，扩大眼部保健服务的覆盖范围和教育措施进一步刺激了对青光眼治疗的需求。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球青光眼治疗市场的各个细分市场进行了包容性评估。青光眼治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

青光眼治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

依产品类型

• 前列腺素类似物 (PGA)
• 阿尔法激动剂
• 贝塔博克
• 胆碱能
• 碳酸酐酶抑制
• 联合用药

按指示

• 角状青光眼 (ACG)
• 开角型青光眼 (OAC)
• 继发性青光眼
• 先天性青光眼
• 其他适应症

按销售管道

• 医院药房
• 零售药局
• 网上销售

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲青光眼治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。青光眼治疗市场的主要参与者包括诺华公司、辉瑞公司、默克公司、博士伦公司、艾尔建公司、百里高公司、梯瓦製药工业有限公司、Akorn Inc、Mobius Therapeutics LLC。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：青光眼治疗 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 市场吸引力分析：按产品类型
  • 按指标进行的市场吸引力分析
  • 按销售管道分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球青光眼治疗市场分析：依产品类型

• 概述：按产品类型
• 历史和预测数据
• 分析：依产品类型
• 前列腺素类似物 (PGA)
• 阿尔法激动剂
• 贝塔博克
• 胆碱能
• 碳酸酐酶抑制
• 联合用药

第 6 章：全球青光眼治疗市场分析：依适应症分类

• 按适应症概述
• 历史和预测数据
• 按指标分析
• 角状青光眼 (ACG)
• 开角型青光眼 (OAC)
• 继发性青光眼
• 先天性青光眼
• 其他适应症

第 7 章：全球青光眼治疗市场分析：按销售管道

• 销售通路概览
• 历史和预测数据
• 按销售管道分析
• 医院药房
• 零售药局
• 网上销售

第 8 章：全球青光眼治疗市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 9 章：青光眼治疗公司的竞争格局

• 青光眼治疗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 10 章：公司简介

• 公司股份分析
• 市场集中度
• Novartile AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Merck & Co. Ine
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bausch & Lomb Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Allergan Plc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Perrigo Plc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Teva Pharmaceutical Industries Ltd
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Akorn Inc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Mobius Therapeutics LLC
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Glaucoma Treatment Market is presumed to reach the market size of nearly USD 12.1 BN by 2032 from USD 7.66 BN in 2023 with a CAGR of 5.21% under the study period 2024 - 2032.

The treatment of glaucoma involves a range of medical and surgical interventions to manage and control the progression of eye conditions. In glaucoma, the optic nerve is damaged, which is often linked to elevated intraocular pressure (IOP). As a leading cause of irreversible blindness, there is currently no cure for glaucoma. However, treatment strategies are focused on preventing additional damage to the optic nerve and preserving vision.

MARKET DYNAMICS

The Glaucoma treatment market is propelled by various factors responding to the increasing global prevalence of glaucoma, particularly among the aging population. Technological advancements in treatment options, including laser therapies and minimally invasive glaucoma surgeries (MIGS), contribute to the expansion of effective interventions. Rising awareness and early detection efforts emphasize the demand for diverse treatment options to address varying patient needs. The preference for minimally invasive procedures, such as MIGS, influences patient choices, offering reduced recovery times and improved outcomes. Increased healthcare expenditure, government initiatives supporting eye health, and collaborations among industry stakeholders drive innovation in glaucoma treatment. The competitive market landscape and continuous product development contribute to the introduction of new and improved treatment modalities. Additionally, expanding access to eye care services and educational initiatives further fuel the demand for glaucoma treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of glaucoma treatment. The growth and trends of glaucoma treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the glaucoma treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Prostaglandin Analogs (PGAs)
• Alpha Agonnist
• Beta Borkers
• Cholinergic
• Carbonic Anhydrase Inhibitom
• Combined Medications

By Indication

• Angle Clasura Glaucoma (ACG)
• Open Angle Glaucuma (OAC)
• Secondary Glaucoma
• Congenital Glaucoma
• Other Indications

By Sales Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Glaucoma Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Glaucoma Treatment market include Novartile AG, Pfizer Inc, Merck & Co. Ine, Bausch & Lomb Inc., Allergan Plc, Perrigo Plc, Teva Pharmaceutical Industries Ltd, Akorn Inc, Mobius Therapeutics LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . GLAUCOMA TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Sales Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY PRODUCT TYPE

• 5.1 Overview by Product Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Product Type
• 5.4 Prostaglandin Analogs (PGAs) Historic and Forecast Sales by Regions
• 5.5 Alpha Agonnist Historic and Forecast Sales by Regions
• 5.6 Beta Borkers Historic and Forecast Sales by Regions
• 5.7 Cholinergic Historic and Forecast Sales by Regions
• 5.8 Carbonic Anhydrase Inhibitom Historic and Forecast Sales by Regions
• 5.9 Combined Medications Historic and Forecast Sales by Regions

6 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY INDICATION

• 6.1 Overview by Indication
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Indication
• 6.4 Angle Clasura Glaucoma (ACG) Historic and Forecast Sales by Regions
• 6.5 Open Angle Glaucuma (OAC) Historic and Forecast Sales by Regions
• 6.6 Secondary Glaucoma Historic and Forecast Sales by Regions
• 6.7 Congenital Glaucoma Historic and Forecast Sales by Regions
• 6.8 Other Indications Historic and Forecast Sales by Regions

7 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY SALES CHANNEL

• 7.1 Overview by Sales Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Sales Channel
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Sales Historic and Forecast Sales by Regions

8 . GLOBAL GLAUCOMA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE GLAUCOMA TREATMENT COMPANIES

• 9.1. Glaucoma Treatment Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF GLAUCOMA TREATMENT INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Novartile AG
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Pfizer Inc
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Merck & Co. Ine
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Bausch & Lomb Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Allergan Plc
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Perrigo Plc
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Teva Pharmaceutical Industries Ltd
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Akorn Inc
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Mobius Therapeutics LLC
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product Type (USD MN)
• Prostaglandin Analogs (PGAs) Market Sales by Geography (USD MN)
• Alpha Agonnist Market Sales by Geography (USD MN)
• Beta Borkers Market Sales by Geography (USD MN)
• Cholinergic Market Sales by Geography (USD MN)
• Carbonic Anhydrase Inhibitom Market Sales by Geography (USD MN)
• Combined Medications Market Sales by Geography (USD MN)
• Analysis Market by Indication (USD MN)
• Angle Clasura Glaucoma (ACG) Market Sales by Geography (USD MN)
• Open Angle Glaucuma (OAC) Market Sales by Geography (USD MN)
• Secondary Glaucoma Market Sales by Geography (USD MN)
• Congenital Glaucoma Market Sales by Geography (USD MN)
• Other Indications Market Sales by Geography (USD MN)
• Analysis by Sales Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Sales Market Sales by Geography (USD MN)
• Global Glaucoma Treatment Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Glaucoma Treatment Report
• Market Research Process
• Market Research Methodology
• Global Glaucoma Treatment Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product Type
• Market Attractiveness Analysis by Indication
• Market Attractiveness Analysis by Sales Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product Type (USD MN)
• Prostaglandin Analogs (PGAs) Market Sales by Geography (USD MN)
• Alpha Agonnist Market Sales by Geography (USD MN)
• Beta Borkers Market Sales by Geography (USD MN)
• Cholinergic Market Sales by Geography (USD MN)
• Carbonic Anhydrase Inhibitom Market Sales by Geography (USD MN)
• Combined Medications Market Sales by Geography (USD MN)
• Global Market Analysis by Indication (USD MN)
• Angle Clasura Glaucoma (ACG) Market Sales by Geography (USD MN)
• Open Angle Glaucuma (OAC) Market Sales by Geography (USD MN)
• Secondary Glaucoma Market Sales by Geography (USD MN)
• Congenital Glaucoma Market Sales by Geography (USD MN)
• Other Indications Market Sales by Geography (USD MN)
• Global Market Analysis by Sales Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Sales Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.